10x Genomics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from 10x Genomics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Debt due within a year is covered 12.4 times by its yearly operating cash. Higher than 87% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
1.9×Over the last 3 years its own operating cash covered its investment spending (capex) 1.9 times.
Higher than 73% of Healthcare companies in United States.
Cash Locked Ratio
$18For every $100 of sales, $18 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $31 tied up three years earlier.
Less money tied up than 63% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
$97Sales grew 24% in 3 years; of every extra $100 of sales, $97 became extra profit.
Higher than 80% of Healthcare companies in United States.
Asset Productivity Ratio
+24% / +1%In 3 years sales changed by +24% while total assets changed by +1%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
12.4×Debt due within a year is covered 12.4 times by its yearly operating cash.
Higher than 87% of Healthcare companies in United States.
Cash Cushion Ratio
+5%Cash, after subtracting all debt, equals 5% of its market value (net cash).
Lower than 58% of Healthcare companies in United States.
Tangible Assets Ratio
94%Of every $100 the company owns, $94 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 68% of Healthcare companies in United States.
Tangible Net Worth Ratio
92%Of every $100 of net worth, $92 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 74% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
10x Genomics, Inc. made a loss over the last year. 10x Genomics, Inc. owes $0.20 for every $1 it owns. 10x Genomics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
Loss10x Genomics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
11.01The share price is 11.01 times 10x Genomics, Inc.'s book value per share, higher than 88% of Healthcare companies in United States.
Market cap
$9.1 BThe total market value of all of 10x Genomics, Inc.'s shares at today's price (share price × number of shares), larger than 89% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$826 MWhat 10x Genomics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$6.34Net worth divided by the number of shares. The share price of $69.75 is 11.0 times this, which is the P/B above.
Return on equity (ROE)
-9.4%10x Genomics, Inc. lost 9.4% of its shareholders' money over the last year, higher than 72% of Healthcare companies in United States.
Owes vs Owns
0.20×10x Genomics, Inc. owes $0.20 for every $1 it owns (low), lower than 72% of Healthcare companies in United States.
Dividend yield
None10x Genomics, Inc. does not currently pay a dividend.
Revenue growth
+5%Revenue rose 5% in the year to Dec 2025, and grew 8% a year on average over 3 years.
Profit growth
Loss10x Genomics, Inc. made a loss in each of the last two years.
Profit margin
-6.8%10x Genomics, Inc. lost $7 for every $100 of revenue.
Cash vs debt
Net cash10x Genomics, Inc. held $439 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For 10x Genomics, Inc.: $9.1 B ÷ $826 M (30 Jun 2026) = 11.0.
What is 10x Genomics, Inc.'s return on equity?
10x Genomics, Inc. lost 9.4% of its shareholders' money over the last year, higher than 72% of Healthcare companies in United States.
How much does 10x Genomics, Inc. owe compared with what it owns?
10x Genomics, Inc. owes $0.20 for every $1 it owns (low), lower than 72% of Healthcare companies in United States.
Does 10x Genomics, Inc. pay a dividend?
No. 10x Genomics, Inc. does not currently pay a dividend.
Is 10x Genomics, Inc.'s revenue growing?
Revenue rose 5% in the year to Dec 2025, and grew 8% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.